Amy M. Wood

Cooley advised BroadSoft, the technology innovator in cloud PBX, unified communications, team collaboration and contact center solutions for businesses and service providers, on its sale to worldwide technology leader Cisco.

Cooley advised Jazz Pharmaceuticals on its $1.5 billion acquisition of Celator. The transaction adds the orphan drug VYXEOS which aims to treat AML. Jazz Pharmaceuticals, a Cooley client since 2006, is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs.

Cooley advised the underwriters on Xenon Pharmaceuticals' initial public offering. Xenon is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. Xenon has built a core-enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. The company now trades on the Nasdaq Global Market under the symbol "XENE."

Jefferies and Wells Fargo Securities acted as the joint book-running managers and Canaccord Genuity acted as co-manager for the offering.

Cooley is advising NetScout Systems on its definitive agreement to acquire the communications business of Danaher for $2.6 billion. According to The Wall Street Journal, the acquisition will create a global cybersecurity and IT management company.

NetScout is a market leading provider of performance analytics and operational intelligence solutions. Danaher is an industrial and health care technology company, whose communications businesses specialize in protecting and improving network performance through testing, monitoring and threat protection.

Seattle – Cooley advised Alder Biopharmaceuticals on its $80 million initial public offering. Alder is a Washington-based clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder is currently developing two lead product candidates: ALD403, an investigational monoclonal antibody for migraine, and Clazakizumab, an investigational monoclonal antibody for rheumatoid arthritis and other autoimmune indications, in collaboration with Bristol-Myers Squibb. The company now trades on the Nasdaq Global Stock Market under the symbol "ALDR."